Horizon Therapeutics [HZNP] vs Johnson & Johnson [JNJ] Detailed Stock Comparison

Horizon Therapeutics Plc

NASDAQ
Loading...

Johnson & Johnson

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Horizon Therapeutics Plc wins in 4 metrics, Johnson & Johnson wins in 13 metrics, with 0 ties. Johnson & Johnson appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Horizon Therapeutics Plc Johnson & Johnson Better
P/E Ratio (TTM) 61.86 20.49 Johnson & Johnson
Price-to-Book Ratio 5.01 6.68 Horizon Therapeutics Plc
Debt-to-Equity Ratio 0.48 60.50 Horizon Therapeutics Plc
PEG Ratio -16.29 0.42 Johnson & Johnson
EV/EBITDA 24.08 16.84 Johnson & Johnson
Profit Margin (TTM) 74.64% 21.83% Horizon Therapeutics Plc
Operating Margin (TTM) 16.83% 26.72% Johnson & Johnson
EBITDA Margin (TTM) 16.83% 26.72% Johnson & Johnson
Return on Equity 10.28% 32.87% Johnson & Johnson
Return on Assets (TTM) 5.72% 13.46% Johnson & Johnson
Free Cash Flow (TTM) N/A $19.31B N/A
Dividend Yield N/A 2.09% N/A
1-Year Return -6.82% 53.32% Johnson & Johnson
Price-to-Sales Ratio (TTM) 7.34 5.66 Johnson & Johnson
Enterprise Value $26.84B $574.25B Johnson & Johnson
EV/Revenue Ratio 7.40 5.96 Johnson & Johnson
Gross Profit Margin (TTM) 76.72% 67.56% Horizon Therapeutics Plc
Revenue per Share (TTM) $16 $40 Johnson & Johnson
Earnings per Share (Diluted) $2.22 $11.04 Johnson & Johnson
Beta (Stock Volatility) N/A 0.33 N/A
Short % of Float N/A 1.03% N/A

Horizon Therapeutics Plc vs Johnson & Johnson Stock Performance Analysis

Loading Price Chart...

HZNP
JNJ

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Horizon Therapeutics Plc0.00%N/AN/AN/AN/AN/A
Johnson & Johnson-2.16%1.51%3.95%-3.10%10.03%13.65%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Horizon Therapeutics Plc-6.82%74.04%9.84%176.66%176.66%176.66%
Johnson & Johnson53.32%46.67%48.70%108.58%263.36%290.52%

Performance & Financial Health Analysis: Horizon Therapeutics Plc vs Johnson & Johnson

MetricHZNPJNJ
Market Information
Market Cap i$26.63B$555.84B
Market Cap CategoryLarge capMega cap
10 Day Avg. Volume i19,134,2068,370,566
90 Day Avg. Volume i8,460,6957,752,965
Last Close$116.30$235.66
52 Week Range$116.30 - $116.34$149.04 - $251.71
% from 52W High-0.03%-6.38%
All-Time High$39.49 (Jul 20, 2015)$251.71 (Mar 02, 2026)
% from All-Time High194.50%-6.38%
Growth Metrics
Quarterly Revenue Growth0.14%0.10%
Quarterly Earnings GrowthN/A-0.52%
Financial Health
Profit Margin (TTM) i0.75%0.22%
Operating Margin (TTM) i0.17%0.27%
Return on Equity (TTM) i0.10%0.33%
Debt to Equity (MRQ) i0.4860.50
Cash & Liquidity
Book Value per Share (MRQ)$23.22$33.87
Cash per Share (MRQ)N/A$8.34
Operating Cash Flow (TTM) i$1.33B$22.21B
Levered Free Cash Flow (TTM) i$1.81B$43.47B
Dividends
Last 12-Month Dividend Yield iN/A2.09%
Last 12-Month Dividend iN/A$5.20

Valuation & Enterprise Metrics Analysis: Horizon Therapeutics Plc vs Johnson & Johnson

MetricHZNP (Apr 30, 2025)JNJ (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i61.8620.49
Forward P/E i20.5517.80
PEG Ratio i-16.290.42
Price to Sales (TTM) i7.345.66
Price to Book (MRQ) i5.016.68
Market Capitalization
Market Capitalization i$26.63B$555.84B
Enterprise Value i$26.84B$574.25B
Enterprise Value Metrics
Enterprise to Revenue i7.405.96
Enterprise to EBITDA i24.0816.84
Risk & Other Metrics
Beta iN/A0.33
Book Value per Share (MRQ) i$23.22$33.87

Financial Statements Comparison: Horizon Therapeutics Plc vs Johnson & Johnson

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricHZNPJNJ (2025)
Revenue/Sales iN/A94.19B
Cost of Goods Sold iN/A30.26B
COGS % of Revenue i-32.1%
Gross Profit iN/A63.94B
Gross Margin i-67.9%
Research & Development iN/A14.67B
Operating Income (EBIT) iN/A25.60B
Operating Margin i-27.2%
EBITDA iN/A35.16B
EBITDA Margin i-37.3%
Pre-Tax Income iN/A32.58B
Pre-Tax Income % of Revenue i-34.6%
Income Tax iN/A5.78B
Income Tax % of Revenue i-6.1%
Net Income (Profit) iN/A26.80B
Profit Margin i-28.5%

Balance Sheet & Liquidity Metrics

MetricHZNPJNJ (2025)
Cash & Equivalents iN/A19.71B
Total Current Assets iN/A55.62B
Total Current Assets % of Revenue i-59.1%
Total Current Liabilities iN/A54.13B
Total Current Liabilities % of Revenue i-57.5%
Long-Term Debt iN/A39.44B
Long-Term Debt % of Revenue i-41.9%
Total Shareholders Equity iN/A81.54B
Retained Earnings iN/AN/A
Retained Earnings % of Revenue i-0.0%
Property, Plant & Equipment iN/A0

Cash Flow Statement Comparison

MetricHZNPJNJ (2025)
Operating Cash Flow iN/A22.21B
Operating Cash Flow % of Revenue i-23.6%
Capital Expenditures iN/A-4.83B
Free Cash Flow iN/A19.31B
FCF Margin i-20.5%
Debt Repayment iN/A-14.09B
Common Stock Repurchase iN/A-5.95B

Short Interest & Institutional Ownership Analysis

MetricHZNPJNJ
Shares Short iN/A22.27M
Short Ratio iN/A2.90
Short % of Float iN/A1.03%
Shares Outstanding i229.00M2.41B
Float Shares iN/A2.41B
% Held by Insiders iN/A0.06%
% Held by Institutions iN/A75.84%
% Held by Public iN/A24.10%

Dividend Analysis & Yield Comparison: Horizon Therapeutics Plc vs Johnson & Johnson

MetricHZNPJNJ
Last 12-Month Dividend iN/A$5.20
Last 12-Month Dividend Yield iN/A2.09%
3-Year Avg Annual Dividend iN/A$4.97
3-Year Avg Dividend Yield iN/A0.74%
3-Year Total Dividends iN/A$14.92
Ex-Dividend DateN/AFeb 24, 2026